Literature DB >> 16521279

Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice.

Charles H Cook1, Yingxue Zhang, Daniel D Sedmak, Larry C Martin, Scott Jewell, Ronald M Ferguson.   

Abstract

OBJECTIVE: Cytomegalovirus (CMV) is a ubiquitous herpes virus that persists in the host in a latent state following primary infection. We have recently observed that CMV reactivates in lungs of critically ill surgical patients and that this reactivation can be triggered by bacterial sepsis. Although CMV is a known pathogen in immunosuppressed transplant patients, it is unknown whether reactivated CMV is a pathogen in immunocompetent hosts. Using an animal model of latency/reactivation, we studied the pathobiology of CMV reactivation in the immunocompetent host.
DESIGN: Laboratory study.
SETTING: University laboratory.
SUBJECTS: Cohorts of immunocompetent BALB/c mice with or without latent murine CMV (MCMV+/MCMV-).
INTERVENTIONS: Mice underwent cecal ligation and puncture. Lung tissue homogenates were evaluated after cecal ligation and puncture for tumor necrosis factor-alpha, interleukin-1beta, neutrophil chemokine KC, and macrophage inflammatory protein-2 messenger RNA by polymerase chain reaction and real-time quantitative reverse transcription-polymerase chain reaction. Because pulmonary tumor necrosis factor-alpha expression is known to cause pulmonary fibrosis, trichrome-stained sections of lung tissues were analyzed using image analysis to quantitate pulmonary fibrosis. In a second experiment, a cohort of MCMV+ mice received ganciclovir (10 mg/kg/day subcutaneously) following cecal ligation and puncture. Tumor necrosis factor-alpha messenger RNA and pulmonary fibrosis were evaluated as described previously.
MEASUREMENTS AND MAIN RESULTS: All MCMV+ mice had CMV reactivation beginning 2 wks after cecal ligation and puncture. Following reactivation, these mice had abnormal tumor necrosis factor-alpha, interleukin-1beta, neutrophil chemokine KC, and macrophage inflammatory protein-2 messenger RNA expression compared with controls. Image analysis showed that MCMV+ mice had significantly increased pulmonary fibrosis compared with MCMV- mice 3 wks after cecal ligation and puncture. Ganciclovir treatment following cecal ligation and puncture prevented MCMV reactivation. Furthermore, ganciclovir-treated mice did not demonstrate abnormal pulmonary expression of tumor necrosis factor-alpha messenger RNA. Finally, ganciclovir treatment prevented pulmonary fibrosis following MCMV reactivation.
CONCLUSIONS: This study shows that CMV reactivation causes abnormal tumor necrosis factor-alpha expression, and that following CMV reactivation, immunocompetent mice have abnormal pulmonary fibrosis. Ganciclovir blocks MCMV reactivation, thus preventing abnormal tumor necrosis factor-alpha expression and pulmonary fibrosis. These data may explain a mechanism by which critically ill surgical patients develop fibroproliferative acute respiratory distress syndrome. These data suggest that human studies using antiviral agents during critical illness are warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16521279      PMCID: PMC1894751          DOI: 10.1097/01.ccm.0000201876.11059.05

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  52 in total

1.  The pulmonary inflammatory response to experimental fecal peritonitis: relative roles of tumor necrosis factor-alpha and endotoxin.

Authors:  M A Mercer-Jones; M Heinzelmann; J C Peyton; D J Wickel; M Cook; W G Cheadle
Journal:  Inflammation       Date:  1997-08       Impact factor: 4.092

2.  Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung.

Authors:  P J Sime; Z Xing; F L Graham; K G Csaky; J Gauldie
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  The roles of tumour necrosis factor-alpha, interleukin-1 and interleukin-12 in murine cytomegalovirus infection.

Authors:  S T Yerkovich; S D Olver; J C Lenzo; C D Peacock; P Price
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

4.  The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection.

Authors:  A D Yurochko; E S Hwang; L Rasmussen; S Keay; L Pereira; E S Huang
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters.

Authors:  A D Yurochko; M W Mayo; E E Poma; A S Baldwin; E S Huang
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice.

Authors:  R H Rubin; P Lynch; M S Pasternack; D Schoenfeld; D N Medearis
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Lungs are a major organ site of cytomegalovirus latency and recurrence.

Authors:  M Balthesen; M Messerle; M J Reddehase
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  Detection of latent cytomegalovirus DNA in diverse organs of mice.

Authors:  T Collins; C Pomeroy; M C Jordan
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

9.  Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegalovirus infection.

Authors:  T F Kowalik; B Wing; J S Haskill; J C Azizkhan; A S Baldwin; E S Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

10.  Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation.

Authors:  S Huang; J D Paulauskis; J J Godleski; L Kobzik
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

View more
  39 in total

1.  Right place, right time: the evolving role of herpesvirus infection as a "second hit" in idiopathic pulmonary fibrosis.

Authors:  Jonathan A Kropski; William E Lawson; Timothy S Blackwell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-16       Impact factor: 5.464

2.  Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice.

Authors:  Charles H Cook; Joanne Trgovcich; Peter D Zimmerman; Yingxue Zhang; Daniel D Sedmak
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: pro.

Authors:  Jean-Marie Forel; Ignacio Martin-Loeches; Charles-Edouard Luyt
Journal:  Intensive Care Med       Date:  2014-11-01       Impact factor: 17.440

Review 4.  Impact of cytomegalovirus load on host response to sepsis.

Authors:  Thomas Marandu; Michael Dombek; Charles H Cook
Journal:  Med Microbiol Immunol       Date:  2019-04-11       Impact factor: 3.402

Review 5.  Current Understanding of Cytomegalovirus Reactivation in Critical Illness.

Authors:  Hannah Imlay; Ajit P Limaye
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 6.  Viral latency drives 'memory inflation': a unifying hypothesis linking two hallmarks of cytomegalovirus infection.

Authors:  Christof K Seckert; Marion Griessl; Julia K Büttner; Sabine Scheller; Christian O Simon; Kai A Kropp; Angélique Renzaho; Birgit Kühnapfel; Natascha K A Grzimek; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2012-09-19       Impact factor: 3.402

7.  Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice.

Authors:  Meghan R Forster; Joanne Trgovcich; Peter Zimmerman; Alexander Chang; Cortland Miller; Paul Klenerman; Charles H Cook
Journal:  Antiviral Res       Date:  2009-12-11       Impact factor: 5.970

8.  Cytomegalovirus in the intensive care unit: pathogen or passenger?

Authors:  Jeffrey I Cohen
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

9.  Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies.

Authors:  Peter D Burbelo; Alexandra T Issa; Kathryn H Ching; Maurice Exner; W Lawrence Drew; Harvey J Alter; Michael J Iadarola
Journal:  Virol J       Date:  2009-05-01       Impact factor: 4.099

Review 10.  Cytomegalovirus infection in critically ill patients: a systematic review.

Authors:  Ryosuke Osawa; Nina Singh
Journal:  Crit Care       Date:  2009-05-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.